Company Filing History:
Years Active: 2022
Title: Durga Prasanna Kumar C H: Innovator in Therapeutics
Introduction
Durga Prasanna Kumar C H is an esteemed inventor based in Bengaluru, India. He is known for his significant contributions in the field of pharmaceuticals, particularly in developing novel therapeutic compounds. With one patent to his name, Kumar is making strides in addressing various critical health conditions.
Latest Patents
Kumar's patent, titled "Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors," showcases his innovative approach to medicinal chemistry. This disclosure describes novel compounds represented by a general formula, including their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs. These compounds have demonstrated potential in inhibiting both LSD and HDAC, making them valuable as therapeutic agents in treating diseases related to cellular growth, such as malignant tumors, schizophrenia, Alzheimer's disease, and Parkinson's disease.
Career Highlights
Durga Prasanna Kumar C H currently works at Jubilant Epicore LLC, where he collaborates with talented individuals in the field. His expertise in pharmaceutical innovation is complemented by his role in a thriving company that focuses on developing cutting-edge therapeutic solutions.
Collaborations
Throughout his career, Kumar has had the opportunity to work with colleagues like Sridharan Rajagopal and Mahanandeesha S Hallur. These collaborations enhance the creative and innovative environment necessary for groundbreaking research and development in pharmaceuticals.
Conclusion
In summary, Durga Prasanna Kumar C H is a remarkable inventor whose work has the potential to make a significant impact on healthcare. His patent on dual LSD1/HDAC inhibitors highlights his dedication to creating innovative solutions for critical health issues. As he continues his work at Jubilant Epicore LLC, it will be exciting to see how his contributions shape the future of therapeutics.